Dual CCR9/CD1a CAR-T Cell Therapy for T-ALL
CCR9 expressed on >70% of T-ALL patients; dual targeting CCR9/CD1a achieves 86% patient coverage while preventing T cell aplasia.
FELIX Study: Long-Term Obe-cel CAR T-Cell Outcomes in Relapsed/Refractory B-Cell ALL
Obe-cel CAR T shows 54% 2-year remission rate in B-cell ALL; earlier treatment & Ph+ disease improve outcomes.
Read More